Sensorion Announces its Participation in the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

About this update from Sensorion Sas

[{"type":"text","content":"MONTPELLIER, France, May 05, 2026--(BUSINESS WIRE)--Regulatory News:","length":68,"tagName":"p"},{"type":"text","content":"Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent loss disorders, today announces its participation in the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking place on May 11-15, 2026, in Boston, United-States.","length":357,"tagName":"p"},{"type":"text","content":"Laurent Desire, Head of Preclinical Development at Sensorion, will present the following presentation at the ASGCT meeting:Presentation type: Poster PresentationTitle: Safety, biodistribution and efficacy of SENS-601, an AAV-based gene therapy treatment candidate for the autosomal recessive non-syndromic deafness 1A (DFNB1A)Date: Tuesday, May 12, 2026Time: 5pm to 6:30 pm ETRoom: Thomas M. Menino Convention & Exhibition Center (MCEC) Halls B2-C, Exhibit Level","length":471,"tagName":"p"},{"type":"text","content":"Marina Dos Santos, DSP Manager at Sensorion, will present the following presentation at the ASGCT meeting:Presentation type: Poster PresentationTitle: Development and scale-up of an enrichment step for a difficult-to-produce recombinant AAV serotypeDate: Tuesday, May 12, 2026Time: 5pm to 6:30 pm ETRoom: Thomas M. Menino Convention & Exhibition Center (MCEC) Halls B2-C, Exhibit Level","length":394,"tagName":"p"},{"type":"text","content":"About SensorionSensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat, and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and mechanisms of action for drug candidates.","length":462,"tagName":"p"},{"type":"text","content":"It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness, developed in the framework of its broad strategic collaboration focused on the genetics of hearing with the Institut Pasteur. GJB2-GT (SENS-601) is the Company’s lead gene therapy program, targeting hearing loss related to mutations in the GJB2 gene to addr...

More updates from Sensorion Sas